These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25382829)

  • 21. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
    Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients.
    Schep SJ; Fischer K; Boes M; Schutgens REG
    Haemophilia; 2023 Jul; 29(4):1039-1048. PubMed ID: 37276354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 24. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
    Recht M; Nemes L; Matysiak M; Manco-Johnson M; Lusher J; Smith M; Mannucci P; Hay C; Abshire T; O'Brien A; Hayward B; Udata C; Roth DA; Arkin S
    Haemophilia; 2009 Jul; 15(4):869-80. PubMed ID: 19473411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
    Musso R
    Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.
    Soucie JM; Miller CH; Kelly FM; Payne AB; Creary M; Bockenstedt PL; Kempton CL; Manco-Johnson MJ; Neff AT;
    Haemophilia; 2014 Mar; 20(2):230-7. PubMed ID: 24261612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
    Gouw SC; van den Berg HM; le Cessie S; van der Bom JG
    J Thromb Haemost; 2007 Jul; 5(7):1383-90. PubMed ID: 17456190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
    Scharrer I; Bray GL; Neutzling O
    Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A.
    Aznar JA; Moret A; Ibáñez F; Vila C; Cabrera N; Mesa E; Bonanad S
    Haemophilia; 2014 Sep; 20(5):624-9. PubMed ID: 24697977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
    Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
    Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.
    Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP
    Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A.
    Delumeau JC; Ikegawa C; Yokoyama C; Haupt V
    Thromb Haemost; 2008 Jul; 100(1):32-7. PubMed ID: 18612535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.
    Lusher JM; Lee CA; Kessler CM; Bedrosian CL;
    Haemophilia; 2003 Jan; 9(1):38-49. PubMed ID: 12558777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII.
    Hooimeijer LH; Stein-Wit MA; Voskuilen MA; Lukens MV; Meijer K; Mäkelburg AB; Tamminga RY
    Clin Appl Thromb Hemost; 2023; 29():10760296231167416. PubMed ID: 36998198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients.
    Roussel-Robert V; Torchet MF; Legrand F; Rothschild C; Stieltjes N
    J Thromb Haemost; 2003 Nov; 1(11):2450-1. PubMed ID: 14629482
    [No Abstract]   [Full Text] [Related]  

  • 40. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors.
    Unuvar A; Warrier I; Lusher JM
    Haemophilia; 2000 May; 6(3):150-7. PubMed ID: 10792472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.